Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer-Reference-Cited by-同舟云学术

Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

Published:2024-05 Issue:5 Volume:43 Page:114174
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Blawski Ryan,Vokshi Bujamin H.,Guo Xinyu,Kittane Srushti,Sallaku Mirna,Chen Wanlu,Gjyzari Martina,Cheung Tony,Zhang Yuhan,Simpkins Christopher,Zhou Weiqiang,Kulick Amanda,Zhao Peihua,Wei Meihan,Shivashankar Pranavkrishna,Prioleau Tatiana,Razavi Pedram,Koche Richard,Rebecca Vito W.,de Stanchina Elisa,Castel Pau,Chan Ho Man,Scaltriti Maurizio,Cocco Emiliano,Ji Hongkai,Luo Minkui,Toska Eneda^ORCID

Funder

NCI

Publisher

Elsevier BV

Reference45 articles.

1. Overcoming Endocrine Resistance in Breast Cancer;Hanker;Cancer Cell,2020

2. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer;Bosch;Sci. Transl. Med.,2015

3. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer;André;N. Engl. J. Med.,2019

4. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D;Toska;Science,2017

5. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression;Toska;Cell Rep.,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy;Pharmacological Research;2024-10